We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation
News

BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation

BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation
News

BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioFocus has announced that it has received a Rapid Response Innovation Award from The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.

BioFocus will use the investment to develop a high-throughput, high-content assay platform to support the discovery of targets and agents that break the pathogenic loop between glucocerebrosidase (GBA) and a-synuclein, considered to be a major mechanism leading to Parkinson’s disease.

The project is further supported by a new collaboration between BioFocus and Professor Tony Schapira, Institute of Neurology, University College London, a renowned medical researcher in Parkinson’s disease.

Prof. Tony Schapira commented: “The link between mutations in the GBA gene and Parkinson’s disease has been affirmed by multiple clinical studies. The development of a disease-relevant cell model system to support drug discovery on this mechanism will be a critical asset to the Parkinson’s disease research community.”

Prof. Julie Frearson, Senior Director Scientific Alliances and Translational Research, BioFocus, said: “We are delighted and honored to receive this grant. This funding will allow BioFocus to continue tackling novel and challenging therapeutic mechanisms in Parkinson’s disease.”

Advertisement